New Enterprise Associates, of Baltimore, named Christopher Shen principal. He will focus on biotechnology and medical device investments.
Newron Pharmaceuticals SpA, of Gerenzano, Italy, appointed Christophe Bourrilly vice president, finance and Marco Caremi vice president, business development.
North Carolina Biotechnology Center, of Research Triangle Park, N.C., named Paul Wood vice president of business and technology development.
Novuspharma SpA, of Milan, Italy, appointed Karl Hanks manager of investor relations and corporate communications.
Noxxon Pharma AG, of Berlin, promoted Michael Courtney to chief operating officer.
Oncology Inc., of San Antonio, promoted Craig Tooman to senior vice president, strategic planning and corporate communications.
Onyx Pharmaceuticals Inc., of Richmond, Calif., appointed Antonio Grillo-Lopez to its board.
Orchid BioSciences Inc., of Princeton, N.J., appointed Andrew Savadelis chief financial officer and senior vice president of finance.
Osiris Therapeutics Inc., of Baltimore, promoted Mark Pittenger to vice president, research.
Oxford GlycoSciences plc, of Oxford, England, appointed Denis Mulhall chief financial officer and finance director.
Perlegen Sciences Inc., of Mountain View, Calif., added Paul Cusenza as vice president of alliance management.
Quorex Pharmaceuticals Inc., of San Diego, appointed Robert Moellering to its scientific advisory board.
Spherics Inc., of Lincoln, R.I., named David Enscore interim president.
Stem Genetics Inc., of Salt Lake City, added Shohreh Iravani to its scientific advisory board.
Stressgen Biotechnologies Corp., of Victoria, British Columbia, appointed Elizabeth Greetham to its board.
SuperGen Inc., of Dublin, Calif., added Charles Casamento to its board.